Editor's note

Published May 2023. For current modelling across the full new travel vaccines portfolio - including ETEC, Lyme, Zika, and chikungunya - see VAMV090 - New Travel Vaccines Forecast, which includes a primary travel health professional survey.

Post-Pandemic Recovery in Context

International tourist arrivals fell by approximately 72% between 2019 and 2020 as border closures, quarantine requirements, and consumer anxiety suppressed travel demand globally. By the end of FY2022, arrivals were estimated at roughly 63% of 2019 levels, with long-haul routes recovering more slowly than regional travel.

For travel vaccine manufacturers, this translates directly into suppressed volume. Travel clinics saw appointment numbers fall sharply in 2020 and remained below pre-pandemic baselines through 2021 and into 2022. VacZine Analytics estimates travel vaccines were running at approximately 75% of 2019 unit volumes by end-FY2022, with value recovery somewhat faster due to premium product introductions.

Travel market disruption · 2020
-72%

Estimated decline in international tourist arrivals between 2019 and 2020 (UNWTO). Travel vaccine unit volumes tracked closely with this disruption through 2022.

Dengue and Chikungunya: Two Pivotal Launches

Qdenga (TAK-003): Takeda's tetravalent dengue vaccine received EMA approval in December 2022 for individuals aged 4-60 years, without the seroprevalence pre-screening requirement that constrained Sanofi's Dengvaxia. Brazil followed in March 2023. Approximately 11,500 dengue cases were reported in EU travellers between 2015 and 2019 (Gossner CM et al, 2022), providing a commercial floor for the travel indication before endemic market access is added.

VLA1553 (Valneva chikungunya): Valneva's live-attenuated chikungunya vaccine received FDA priority review designation in February 2023, with a PDUFA date in August 2023. The single-dose immunisation schedule - versus multi-dose regimens typical of other travel vaccines - is a material convenience advantage in a travel clinic setting where adherence to multi-visit regimens is historically poor.

The Broader Pipeline

Beyond dengue and chikungunya, the travel vaccine pipeline encompasses several candidates that could materially expand the commercial market. Enterotoxigenic E. coli (ETEC) remains a significant cause of travellers' diarrhoea with no licensed vaccine. Zika virus (VAMV068) returned to low-level endemic transmission in 2022-2023 in parts of Latin America. Lyme borreliosis vaccine development (VAMV024) is progressing through the Pfizer/Valneva VLA15 programme. VacZine Analytics' VAMV090 - New Travel Vaccines Forecast models the combined commercial potential of this pipeline with primary HCP survey data.